These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Cadherin expression in melanocytic naevi and malignant melanomas.
    Author: Cowley GP, Smith ME.
    Journal: J Pathol; 1996 Jun; 179(2):183-7. PubMed ID: 8758211.
    Abstract:
    An immunocytochemical study has been undertaken of cadherin expression in 11 benign melanocytic naevi and 14 malignant melanomas. Anti-pan-cadherin rabbit antibodies, which recognize multiple cadherin subtypes, demonstrated cadherin expression of moderate or strong intensity in 8 of 11 naevi. Expression was restricted to the more superficial melanocytes which possessed abundant cytoplasm (type A melanocytes). More deeply located melanocytes possessing little cytoplasm (type B melanocytes) or having a spindle cell morphology (type C melanocytes) lacked detectable pan-cadherin expression. The monoclonal antibody HECD-1 detected weak E-cadherin immunostaining in all 11 naevi, expression again being limited, with a single exception, to type A melanocytes. Cadherin immunostaining of moderate or strong intensity was detected by the pan-cadherin antibody in all 14 malignant melanomas. In contrast to naevi, cadherin expression in melanomas frequently extended into the deepest portions of the tumours. E-cadherin immunostaining in malignant melanomas was generally much stronger than that seen in naevi, often being of comparable intensity to the pan-cadherin staining. In summary, cadherins are frequently expressed in melanocytic tumours. In naevi, cadherin expression is related to the degree of melanocytic maturation. Cadherin expression, and particularly E-cadherin expression, tends to be greater in malignant melanomas than in naevi.
    [Abstract] [Full Text] [Related] [New Search]